Gastric inhibitory polypeptide and splanchnic blood perfusion: augmentation of the islet blood flow increase in hyperglycemic rats.
The aim of the study was to investigate how the incretin candidate hormone gastric inhibitory polypeptide (GIP) affects splanchnic blood flow, especially pancreatic islet blood flow. For this purpose, male Sprague-Dawley rats were injected intravenously with either saline or GIP (5 or 15 micrograms/kg body weight) 10 min before blood flow measurements by a microsphere technique. Furthermore, 3 min before the blood flow measurements, 1 ml of either saline or 30% D-glucose was given intravenously. All glucose-injected animals were markedly hyperglycemic (> 20 mmol/liter) at the time of the blood flow measurements. Both doses of GIP potentiated basal and glucose-stimulated insulin release. In the normoglycemic rats, the lowest dose of GIP did not affect the blood perfusion to any of the investigated organs. The highest dose of GIP decreased whole pancreatic and duodenal blood flow, whereas islet blood flow was unaffected. As a result, fractional islet blood flow was increased. In the hyperglycemic rats, where the islet blood flow was increased compared with control animals, both doses of GIP further enhanced islet blood flow. No effect on pancreatic, fractional islet, or duodenal blood flow was seen after GIP administration to hyperglycemic animals. It is concluded that administration of GIP can further augment the glucose-induced stimulation of islet blood flow. This may contribute to facilitating release of insulin from the islets.